Neuroadaptations involved in long-term exposure to ADHD pharmacotherapies: Alterations that support dependence liability of these medications

Biomolecules and Therapeutics

Volumn 19, Issue 1, 2011, Pages 9-20

  dela Peńa, Ike C ^a   Ahn, Hyung Seok ^a   Shin, Chan Young ^b   Cheong, Jae Hoon ^a  

^a Sahmyook University   (South Korea)

^b Konkuk University   (South Korea)

Author keywords

Amphetamine; Atomoxetine; Dependence liability; Methylphenidate; Neuroadaptations

Indexed keywords

AMPHETAMINE; AMPHETAMINE DERIVATIVE; ATOMOXETINE; COCAINE; DOPAMINE; METHAMPHETAMINE; METHYLPHENIDATE; NORADRENALIN; TRANSCRIPTION FACTOR;

ADAPTATION; ARTICLE; ATTENTION DEFICIT DISORDER; CELL STRUCTURE; DENDRITIC SPINE; DOPAMINE RELEASE; DOSE RESPONSE; DRUG ABUSE; DRUG DEPENDENCE; DRUG MEGADOSE; DRUG PROTEIN BINDING; DRUG REEXPOSURE; GENE INDUCTION; HUMAN; LOW DRUG DOSE; MESOLIMBIC DOPAMINERGIC SYSTEM; MOLECULARLY TARGETED THERAPY; NERVE CELL PLASTICITY; NEUROADAPTATION; NEUROTRANSMISSION; NONHUMAN; SIGNAL TRANSDUCTION;

ANIMALIA;

EID: 79851480674     PISSN: 19769148     EISSN: 20054483     Source Type: Journal    
DOI: 10.4062/biomolther.2011.19.1.009     Document Type: Article

References (157)

1. Ackerman, J. M. and White, F. J. (1990) A10 somatodendritic dopamine autoreceptor sensitivity following withdrawal from repeated cocaine treatment. Neurosci. Lett. 117, 181-187.
2. Adriani, W., Leo, D., Greco, D., Rea, M., di Porzio, U., Laviola, G. and Perrone-Capano, C. (2006) Methylphenidate administration to adolescent rats determines plastic changes in reward-related behavior and striatal gene expression. Neuropsychopharmacol. 31, 1946-1956.
3. Amini, B., Yang, P. B., Swann, A. C. and Dafny, N. (2004) Differential locomotor responses in male rats from three strains to acute methylphenidate. Int. J. Neurosci. 114, 1063-1083.
4. Andersen, S. L., LeBlanc, C. J. and Lyss, P. J. (2001) Maturational increases in c-fos expression in the ascending dopamine systems. Synapse 41, 345-350.
5. Andersen, S. L., Arvanitogiannis, A., Pliakas, A. M., LeBlanc, C. and Carlezon, W. A. Jr. (2002) Altered responsiveness to cocaine in rats exposed to methylphenidate during development. Nat. Neurosci. 5, 13-14.
6. Arnsten A. F. (2006) Stimulants: therapeutic actions in ADHD. Neuropsychopharmacol. 31, 2376-2383.
7. Askenasy, E. P., Taber, K. H., Yang, P. B. and Dafny, N. (2007) Methylphenidate (Ritalin): behavioral studies in the rat. Intern. J. Neurosci. 117, 757-794.
8. Banerjee, P. S., Aston, J., Khundakar, A. A. and Zetterstrom, T. S. (2009) Differential regulation of psychostimulant-induced gene expression of brain derived neurotrophic factor and the immediateearly gene arc in the juvenile and adult brain Eur. J. Neurosci. 29, 465-476.
9. Barkley, R. A., Fischer, M., Smallish, L. and Fletcher, K. (2003) Does the treatment of attention-deficit/hyperactivity disorder with stimulants contribute to drug use/abuse? A 13-year prospective study. Pediatrics 111, 97-109.
10. Barron, E., Yang, P. B., Swann, A. C. and Dafny, N. (2009) Adolescent and adult male spontaneous hyperactive rats (SHR) respond differently to acute and chronic methylphenidate (Ritalin). Int. J. Neurosci. 119, 40-58.
11. Beitner-Johnson, D., Guitart, X. and Nestler, E. J. (1992) Neurofi lament proteins and the mesolimbic dopamine system: common regulation by chronic morphine and chronic cocaine in the rat ventral tegmental area. J. Neurosci. 12, 2165-2176.
12. Berke, J. D. and Hyman, S. E. (2000) Addiction, dopamine, and the molecular mechanisms of memory. Neuron 25, 515-532.
13. Biederman, J. and Faraone, S. V. (2005) Attention-defi cit hyperactivity disorder. Lancet. 366, 237-248.
14. Biederman, J., Wigal, S. B., Spencer, T. J., McGough, J. J. and Mays, D. A. (2006) A post hoc subgroup analysis of an 18-day randomized controlled trial comparing the tolerability and effi cacy of mixed amphetamine salts extended release and atomoxetine in schoolage girls with attention-defi cit/hyperactivity disorder. Clin. Ther. 28, 280-293.
15. Bonci, A., Bernardi, G., Grillner, P. and Mercuri, N. B. (2003) The dopamine- containing neuron: maestro or simple musician in the orchestra of addiction. Trends Pharmacol. Sci. 24, 172-177.
16. Bramham, C. R. and Messaoudi, E. (2005). BDNF function in adult synaptic plasticity: the synaptic consolidation hypothesis. Prog. Neurobiol. 76, 99-125.
17. Brandon, C. L. and Steiner, H. (2003) Repeated methylphenidate treatment in adolescent rats alters gene regulation in the striatum. Eur. J. Neurosci. 18, 1584-1592.
18. Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., Morin, S. M., Gehlert, D. R. and Perry, K. W. (2002) Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for effi cacy in attention defi cit/hyperactivity disorder. Neuropsychopharmacol. 27, 699-711.
19. Carlezon, W. A. Jr. and Nestler, E. J. (2002) Elevated levels of GluR1 in the midbrain: a trigger for sensitization to drugs of abuse? Trends Neurosci. 25, 610-615.
20. Chao, J. and Nestler, E. J. (2004) Molecular neurobiology of drug addiction. Annu. Rev. Med. 55, 113-132.
21. Chase, T. D., Brown, R. E., Carrey, N., Wilkinson, M., Chase, T. D., Brown, R. E., Carrey, N. and Wilkinson, M. (2003) Daily methylphenidate administration attenuates c-fos expression in the striatum of prepubertal rats. Neuroreport 14, 769-772.
22. Chase, T. D., Carrey, N., Brown, R. E. and Wilkinson, M. (2005a) Methylphenidate regulates c-fos and fosB expression in multiple regions of the immature rat brain. Brain Res. Dev. Brain Res. 156, 1-12.
23. Chase, T. D., Carrey, N., Brown, R. E. and Wilkinson, M. (2005b) Methylphenidate differentially regulates c-fos and fosB expression in the developing rat striatum. Dev. Brain Res. 157, 181-191.
24. Chase, T., Carrey, N., Soo, E. and Wilkinson, M. (2007) Methylphenidate regulates activity regulated cytoskeletal associated but not brain-derived neurotrophic factor gene expression in the developing rat striatum. Neurosci. 144, 969-984.
25. Commons, K. G. (2010) Neuronal pathways linking substance P to drug addiction and stress. Brain Res. 1314, 175-182.
26. Cotterly, L., Beverley, J. A., Yano, M. and Steiner, H. (2007) Dysregulation of gene induction in corticostriatal circuits after repeated methylphenidate treatment in adolescent rats: Differential effects on zif 268 and homer 1a. Eur. J. Neurosci. 25, 3617-3628.
27. Daunais, J. B. and McGinty, J. F. (1994) Acute and chronic cocaine administration differentially alters striatal opioid and nuclear transcription factor mRNAs. Synapse 18, 35-45.
28. de la Peńa, I. C., Ahn, H. S., Choi, J. Y., Shin, C. Y., Ryu, J. H. and Cheong, J. H. (2011) Methylphenidate self-adminstration and conditioned place preference in an animal model of attention defi cit hyperactivity disorder-the spontaneously hypertensive rat. Behav. Pharmacol. 22, 31-39.
29. Everitt, B. J. and Robbins,T. W. (2005) Neural systems of reinforcement for drug addiction: From actions to habits to compulsion. Nat. Neurosci. 8, 1481-1489.
30. Evans, C., Blackburn, D. and Butt, P. (2004) Use and abuse of methylphenidate in attention-defi cit hyperactivity disorder. CPJ/RPC 137, 30-33.
31. Faraone, S. V. and Biederman, J. (2005) What is the prevalence of adult ADHD? Results of a population screen of 966 adults. J. Atten. Dissord. 9, 384-391.
32. Faraone, S. V., Wigal, S. B. and Hodgkins, P. (2007) Forecasting three-month outcomes in a laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with ADHD. J. Atten. Disord. 11, 74-82.
33. Fumagalli, F., Cattaneo, A., Caffino, L., Ibba, M., Racagni, G., Carboni, E., Gennarelli, M. and Riva, M. A. (2010) Sub-chronic exposure to atomoxetine up-regulates BDNF expression and signalling in the brain of adolescent spontaneously hypertensive rats: Comparison with methylphenidate. Pharmacol. Res. 62, 523-529.
34. Gao, W. Y., Lee, T. H., King, G. R. and Ellinwood, E. H. (1998) Alterations in baseline activity and quinpirole sensitivity in putative dopamine neurons in the substantia nigra and ventral tegmental area after withdrawal from cocaine pretreatment. Neuropsychophamacol. 18, 222-232.
35. Gardier, A. M., Moratalla, R., Cuéllar, B., Sacerdote, M., Guibert, B., Lebrec, H. and Graybiel, A. M. (2000) Interaction between the serotoninergic and dopaminergic systems in d-fenfl uramine-induced activation of cfos and jun B genes in rat striatal neurons. J. Neurochem. 74, 1363-1373.
36. Gasior, M., Bergman, J., Kallman, M. J. and Paronis, C. A. (2005) Evaluation of the reinforcing effects of monoamine reuptake inhibitors under a concurrent schedule of food and i.v. drug delivery in rhesus monkeys. Neuropsychopharmacol. 30, 758-764.
37. Goldman-Rakic, P. S. (1996) Cellular basis of working memory. Neuron 14, 477-485.
38. Grimes, C. A. and Jope, R. S. (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol. 65, 391-426.
39. Grimm, J. W., Lu, L., Hayashi, T., Hope, B. T., Su, T. P. and Shaham, Y. (2003) Time-dependent increases in brain-derived neurotrophic factor protein levels within the mesolimbic dopamine system after withdrawal from cocaine: implications for incubation of cocaine craving. J. Neurosci. 23, 742-747.
40. Guillin, O., Diaz, J., Carroll, P., Griffon, N., Schwartz, J. C. and Sokoloff, P. (2001) BDNF controls dopamine D3 receptor expression and triggers behavioural sensitization. Nature. 411, 86-89.
41. Heal, D. J., Cheetham, S. C. and Smith, S. L. (2009) The neuropharmacology of ADHD drugs in vivo: Insights on effi cacy and safety. Neuropharmacol. 57, 7-8.
42. Hechtman, L. and Greenfield, B. (2003) Long-term use of stimulants in children with attention deficit hyperactivity disorder: safety, efficacy, and long-term outcome. Paediatr. Drugs 5, 787-794.
43. Heil, S. H., Holmes, H. W., Bickel, W. K., Higgins, S. T., Badger, G. J., Laws, H. F. and Faries, D. E. (2002) Comparison of the subjective, physiological, and psychomotor effects of atomoxetine and methylphenidate in light drug users. Drug Alcohol Depend. 67, 149-156.
44. Herges, S. and Taylor, D. A. (1998) Involvement of serotonin in the modulation of cocaine-induced locomotor activity in the rat. Pharmacol. Biochem. Behav. 59, 595-611.
45. Himelstein, J., Newcorn, J. H. and Halperin, J. M. (2000) The neurobiology of attention-deficit hyperactivity disorder. Front. Biosci. 5, D461-D478.
46. Hiroi, N., Brown, J. R., Haile, C. N., Ye, H., Greenberg, M. E. and Nestler, E. J. (1997) FosB mutant mice: Loss of chronic cocaine induction of Fos-related proteins and heightened sensitivity to cocaine's psychomotor and rewarding effects. Proc. Natl. Acad. Sci. USA. 94, 10397-10402.
47. Hooks, M. S., Jones, G. H., Neill, D. B. and Justice, J. B. (1991) Individual differences in amphetamine sensitization: dose-dependent effects. Pharmacol. Biochem. Behav. 41, 203-210.
48. Hope, B., Kosofsky, B., Hyman, S. E. and Nestler, E. J. (1992) Regulation of immediate early gene expression and AP-1 binding in the rat nucleus accumbens by chronic cocaine. Proc. Natl. Acad. Sci. USA. 89, 5764-5768.
49. Horner, K. A., Adams, D. H., Hanson, G. R. and Keefe, K. A. (2005) Blockade of stimulant-induced preprodynorphin mRNA expression in the striatal matrix by serotonin depletion. Neurosci. 131, 67-77.
50. Hyman, S. E. (1996) Addiction to cocaine and amphetamine. Neuron 16, 901-904.
51. Hyman, S. E. and Malenka, R. C. (2001) Addiction and the brain: the neurobiology of compulsion and its persistence. Nat. Rev. Neurosci. 2, 695-703.
52. Jasinski, D. R., Faries, D. E., Moore, R. J., Schuh, L. M. and Allen, A. J. (2008) Abuse liability assessment of atomoxetine in a drug-abusing population. Drug Alcohol Depend. 95, 140-146.
53. Kalivas, P. W. (1993) Neurotransmitter regulation of dopamine neurons in ventral tegmental area. Brain Res. Rev. 18, 75-113.
54. Kalivas, P. W. and Duffy, T. (1998) Repeated cocaine administration alters extracellular glutamate levels in the ventral tegmental area. J. Neurochem. 70, 1497-1502.
55. Kalivas, P. W. and O'Brien, C. (2008) Drug addiction as a pathology of staged neuroplasticity. Neuropsychopharmacol. 33, 166-180.
56. Kankaanpaa, A., Meririnne, E. and Seppälä, T. (2002) 5-HT3 receptor antagonist MDL 72222 attenuates cocaine- and mazindol-, but not methylphenidate-induced neurochemical and behavioral effects in the rat. Psychopharmacol. (Ber) 159, 341-350.
57. Katusic, S. K., Barbaresi, W. J., Colligan, R. C., Weaver, A. L., Leibson, C. L. and Jacobsen, S. J. (2005) Psychostimulant treatment and risk for substance abuse among young adults with a history of attentiondefi cit/hyperactivity disorder: a population-based, birth cohort study. J. Child. Adolesc. Psychopharmacol. 15, 764-776.
58. Kemner, J. E., Starr, H. L., Ciccone, P. E., Hooper-Wood, C. G. and Crockett, R. S. (2005) Outcomes of OROSmethylphenidate compared with atomoxetine in childrenwith ADHD: a multi-center, randomized prospective study. Adv. Ther. 22, 498-512.
59. Kim, H. J., Park, S. H., Kyeong M. K., Ryu, J. H., Cheong, J. H. and Shin, C. Y. (2008) Ever increasing number of animal model systems for attention defi cit/hyperactivity disorder: attention please. Biomol. and Ther. 16, 312-319.
60. Kim, Y., Teylan, M. A., baron, M., Sands, A., Nairn, A. C. and Greengard, P. (2008) Methylphenidate-induced dendritic spine formation and fosB expression in nucleus accumbens. PNAS. 106, 2915-2920.
61. Kiyatkin, E. A. and Rebec, G. V. (1996) Dopaminergic modulation of glutamate-induced excitations of neurons in the neostriatum and nucleus accumbens of awake, unrestrained rats. J. Neurophysiol. 75, 142-153.
62. Koda, K., Ago, Y., Cong, Y., Kita, Y., Takuma, K. and Matsuda, T. (2010) Effects of acute and chronic administration of atomoxetine and methylphenidate on extracellular levels of noradrenaline, dopamine and serotonin in the prefrontal cortex and striatum of mice. J. Neurochem. 114, 259-270.
63. Kollins, S. H., MacDonald, E. K. and Rush, C. R. (2001) Assessing the abuse potential of methylphenidate in nonhuman and human subjects: review. Pharmacol. Biochem. Behav. 68, 611-627.
64. Kollins, S. H. (2003) Comparing the abuse potential of methylphenidate versus other stimulants: a review of available evidence and relevance to the ADHD patient. J. Clin. Psych. 64, 14-18.
65. Koob, G. F., Sanna, P. P. and Bloom, F. E. (1998) Neuroscience of addiction. Neuron 21, 467-476.
66. Koob, G. F. and LeMoal, M. (2001) Drug addiction, dysregulation of reward, and allostasis. Neuropsychopharmacol. 24, 97-129.
67. Kopnisky, K. L. and Hyman, S. E. (2002) Molecular and cellular biology of addiction. In Neuropsychopharmacology: The Fifth Generation of Progress (K. L. Davis, D. Charney, J. T. Coyle, C. Nemeroff, Eds.), pp. 1368-1379. Lippincott Williams and Wilkins, Philadelphia.
68. Kostrzewa, R. M., Reader, T. A. and Descarries, L. (1998) Serotonin neural adaptations to ontogenetic loss of dopamine neurons in rat brain. J. Neurochem. 70, 889-898.
69. Korsching, S., Turgeon, S. M., Pollack, A. E. and Fink, J. S. (1993) The neurotrophic factor concept: a reexamination. J. Neurosci. 13, 2739-2748.
70. Kuczenski, R. and Segal, D. S. (1997) Effects of methylphenidate on extracellular dopamine, serotonin, and norepinephrine: comparison with amphetamine. J. Neurochem. 68, 2032-2037.
71. Kuczenski, R. and Segal, D. S. (2002) Exposure of adolescent rats to oral methylphenidate: preferential effects on extracellular norepinephrine and absence of sensitization and cross-sensitization to methamphetamine. J. Neurosci. 22, 7264-7271.
72. Kuczenski, R. and Segal, D. S. (2005) Stimulant actions in rodents: implications for attention-defi cit/hyperactivity disorder treatment and potential substance abuse. Biol. Psychiatry. 57, 1391-1396.
73. Lagace, D. C., Yee, J. K., Bolaños, C. A. and Eisch, A. J. (2006) Juvenile administration of methylphenidate attenuates adult hippocampal neurogenesis. Biol. Psychiatry 60, 1121-1130.
74. Lambert, N. M. and Hartsong, C. S. (1998) Prospective study of tobacco smoking and substance dependencies among samples of ADHD and non-ADHD participants. J. Learn. Diabil. 31, 533-544.
75. Li, Y., Kolb, B. and Robinson, T. E. (2003) The location of persistent amphetamine-induced changes in the density of dendritic spines on medium spiny neurons in the nucleus accumbens and caudateputamen. Neuropsychopharmacol. 28, 1082-5.
76. Lile, J. A., Stoops, W. W., Durell, T. M., Glaser, P. E. and Rush, C. R. (2006) Discriminative-stimulus, self-reported, performance and cardiovascular effects of atomoxetine in methylphenidate-trained humans. Exp. Clin. Psychopharmacol. 14, 136-147.
77. Lin, J. S., Hou, Y. and Jouvet, M. (1996) Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafi nil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc. Natl. Acad. Sci. USA. 93, 14128-14133.
78. Lu, B. and Figurov, A. (1997) Role of neurotrophins in synapse development and plasticity. Rev. Neurosci. 8, 1-12.
79. Maganti, R. (2004) Neuroscience of psychoactive substance abuse and dependence. Annals of Pharmacother. 38, 1-264.
80. Mandyam, C. D., Wee, S., Crawford, E. F., Eisch, A. J., Richardson, H. N. and Koob, G. F. (2008) Varied access to intravenous methamphetamine self-administration differentially alters adult hippocampal neurogenesis. Biol. Psych. 64, 958-965.
81. Meredith, G. E., Callen, S. and Scheuer D. A. (2002) Brain-derived neurotrophic factor expression is increased in the rat amygdale, piriform cortex and hypothalamus following repeated amphetamine administration. Brain Res. 949, 218-227.
82. Mijnster, M. J., Galis-de Graaf Y. and Voorn, P. (1998) Serotonergic regulation of neuropeptide and glutamic acid decarboxylase mRNA levels in the rat striatum and globus pallidus: studies with fl uoxetine and DOI. Brain Res. Mol. Brain Res. 54, 64-73.
83. Nestler, E. J. (1996) Under siege: the brain on opiates. Neuron. 16, 897-900.
84. Nestler E. J. (2001) Molecular basis of long-term plasticity underlying addiction. Nat. Rev Neurosci. 2, 119-128.
85. Nestler, E. J., Terwilliger, R. Z., Walker, J. R., Sevarino, K. A. and Duman, R. S. (1990) Chronic cocaine treatment decreases levels of the G protein subunits Giα and Goα in discrete regions of rat brain. J. Neurochem. 55, 1079-1082.
86. Newcorn, J. H., Kratochvil, C. J., Allen, A. J., Casat, C. D., Ruff, D. D., Moore, R. J. and Michelson, D. (2008) Atomoxetine and osmotically released methylphenidate for the treatment of attention defi cit hyperactivity disorder: acute comparison and differential response. Am. J. Psych. 165, 721-730.
87. Norrholm, S. D., Bibb, J. A., Nestler, E. J. Ouimet, C. C., Taylor. J. R. and Greengard, P. (2003) Cocaine-induced proliferation of dendritic spines in the nucleus accumbens is dependent on the activity of cyclin-dependent kinase-5. Neurosci. 26, 12308-12313.
88. Okamoto, K. and Aoki, K. (1963) Development of a strain of spontaneously hypertensive rats. Jpn. Circ. J. 27, 282-293.
89. Pandolfo, P., Pamplona, F., Prediger, R. and Takahashi, R. (2007) Increased sensitivity of adolescent spontaneously hypertensive rats, an animal model of attention defi cit hyperactivity disorder, to the locomotor stimulation induced by cannabinoid receptor agonist WIN 55,212-2. Eur. Jour. Pharmacol. 563, 141-148.
90. Pandolfo, P., Vendruscolo, L., Sordi, R. and Takahashi, R. (2009) Cannabinoid-induced conditioned place preference in the spontaneously hypertensive rat-an animal model of attention defi cit hyperactivity disorder. Psychopharmacol. 205, 319-326.
91. Piazza, P. V., Deminiere, J. M., Le Moal, M. and Simon, H. (1989) Factors that predict individual vulnerability to amphetamine selfadministration, Science 245, 1511-1513.
92. Pierce, R. C. and Kalivas, P. W. (1997) A circuitry model of the expression of behavioral sensitization to amphetamine-like psychostimulants. Brain Res. Rev. 25, 192-216.
93. Pierce, R. C., Bell, K., Duffy, P. and Kalivas, P. W. (1996) Repeated cocaine augments excitatory amino acid transmission in the nucleus accumbens only in rats having developed behavioral sensitization. J. Neurosci. 16, 1550-1560.
94. Prasad, S. and Steer, S. (2008) Switching from neurostimulant therapy to atomoxetine in children and adolescents with attention-defi cit hyperactivity disorder: clinical approaches and review of current available evidence. Ped. Drugs 10, 39-47.
95. Pulvirenti, L., Maldonado-Lopez, R. and Koob, G. F. (1992) NMDA receptors in the nucleus accumbens modulate intravenous cocaine but not heroin self-administration in the rat. Brain Res. 594, 327-330.
96. Pulvirenti, L., Berrier, R., Kreifeldt, M. and Koob, G. F. (1994) Modulation of locomotor activity by NMDA receptors in the nucleus accumbens core and shell regions of the rat. Brain Res. 664, 231-236.
97. Rat Genome Database: 2008 (http://rgd.mcw.edu)
98. Reid, M. S. and Berger, S. P. (1996) Evidence for sensitization of cocaine-induced mucleus accumbens glutamate release. Neuroreport 7, 1325-1329.
99. Robinson, L. M., Sclar, D. A., Skaer, T. L. and Galin, R. S. (1999) National trends in the prevalence of attention-defi cit/hyperactivity disorder and the prescribing of methylphenidate among school-age children: 1990-1995. Clin. Pediatr. (Phila). 38, 209-217.
100. Robinson, T. E. and Kolb, B. (1997) Persistent structural modifi cations in nucleus accumbens and prefrontal cortex neurons produced by previous experience with amphetamine. J. Neurosci. 21, 8491-8497.
101. Robinson, T. E. and Kolb, B. (2004) Structural plasticity associated with exposure to drugs of abuse. Neuropharmacol. 47, 33-46.
102. Robinson, T. E. and Berridge, K. C. (1993) The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
103. Robinson, T. E. and Kolb, B. (1999) Alterations in the morphology of dendrites and dendritic spines in the nucleus accumbens and prefrontal cortex following repeated treatment with amphetamine or cocaine. Eur. J. Neurosci. 11, 1598-1604.
104. Russell, V. A., Sagvolden, T. and Johansen, E. B. (2005) Animal models of attention-defi cit hyperactivity disorder. Behav. Brain Funct. 1, 9.
105. Sagvolden, T. and Sergeant, J. A. (1998) Attention defi cit/hyperactivity disorder--from brain dysfunctions to behaviour. Behav. Brain Res. 94, 1-10.
106. Sagvolden, T., Russell, V. A., Aase, H., Johansen, E. B. and Farshbaf, M. (2005a) Rodent models of attention-defi cit/hyperactivity disorder. Biol. Psychiatry 57, 1239-1247.
107. Sagvolden, T., Johansen, E. B., Aase, H. and Russell, V. A. (2005b) A dynamic developmental theory of Attention- Deficit/Hyperactivity Disorder (ADHD) predominantly hyperactive/impulsive and combined subtypes. Behav. Brain. Sci. 28, 397-419.
108. Sagvolden, T., Johansen, E. B., Wøien, G., Walaas, S. I., Storm-Mathisen, J., Bergersen, L. H., Hvalby, O., Jensen, V., Aase, H., Russell, V. A., Killeen, P. R., Dasbanerjee, T., Middleton, F. A. and Faraone S. V. (2009) The spontaneously hypertensive rat model of ADHD-- the importance of selecting the appropriate reference strain. Neuropharmacol. 57, 619-626.
109. See, R. E. and Kalivas, P. W. (2008) Neuroscience of substance abuse and dependence. In Kaplan & Sadock's Comprehensive Textbook of Psychiatry (B. J. Sadock, V. A. Sadock, P. Ruiz, Eds.) pp 387-393. Williams & Wilkins, Lippincott.
110. Segal, D. S. and Kuczenski, R. (1999) Escalating dose-binge treatment with methylphenidate: role of serotonin in the emergent behavioral prolife profi le. J. Pharmacol. Exp. Ther. 291, 19-30.
111. Segal, D. S. and Kuczenski, R. (1987) Individual differences in responsiveness to single and repeated amphetamine administration: behavioral characteristics and neurochemical correlates. J. Pharmacol. Exp. Ther. 242, 917-926.
112. Self, D. W. and Nestler, E. J. (1995) Molecular mechanisms of drug reinforcement and addiction. Annu. Rev. Neurosci. 18, 463-495.
113. Sontag, T., Tucha, O., Walitza, S. and Lange, K. W. (2010) Animal models of attention defi cit/hyperactivity disorder (ADHD): a critical review. ADHD Atten. Def. Hyp. Disord. 2, 1-20.
114. Sorg, B. A., Davidson, D. L., Kalivas, P. W. and Prasad, B. M. (1997) Repeated daily cocaine alters subsequent cocaine-induced increase of extracellular dopamine in the medial prefrontal cortex. J. Pharmacol. Exp. Ther. 281, 54-61.
115. Spangler, R., Zhou, Y., Maggos, C. E., Schlussman, S. D., Ho, A. and Kreek, M. J. (1997) Prodynorphin, proenkephalin and kappa opioid receptor mRNA responses to acute ''binge'' cocaine. Brain Res. Mol. Brain Res. 44, 139-142.
116. Starr, H. L. and Kemner, J. (2005) Multicenter, randomized, open-label study of OROS methylphenidate versus atomoxetine: treatment outcomes in African American children with ADHD. J. Natl. Med. Assoc. 97, 11S-16S.
117. Steiner, H. and Gerfen, C. R. (1993) Cocaine-induced c-fos messenger RNA is inversely related to dynorphin expression in striatum. J. Neurosci. 13, 5066-5081.
118. Steiner, H. and Gerfen, C. R. (1998) Role of dynorphin and enkephalin in the regulation of striatal output pathways and behavior. Exp. Brain Res. 123, 60-76.
119. Steketee, J. D. (2005) Cortical mechanisms of cocaine sensitization. Crit. Rev. Neurobiol. 17, 69-86.
120. Striplin, C. D. and Kalivas, P. W. (1993) Robustness of G protein changes in cocaine sensitization shown with immunoblotting. Synapse 14, 10-15.
121. Swanson, J., McBurnett, K., Christian, D. and Wigal, T. (1995) Stimulant medications and the treatment of children with ADHD. In Advances in Clinical Psychology (T. Ollendick, R. Prinz, Eds.), pp. 265-322. Plenum Press, New York, NY.
122. Swanson, J. M., Sergeant, J. A., Taylor, E., Sonuga-Barke, E. J. S., Jensen, P. S. and Cantwell, D. P. (1998) Attention defi cit disorder and hyperkinetic disorder. Lancet. 351, 429-433.
123. Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, K. A. and Bymaster, F. P. (2006) Effect of the attention defi cit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacol. 50, 755-760.
124. Szumlinski, K., Ary, A. W. and Lominac K. D. (2008) Homers regulate drug-induced neuroplasticity: Implications for addiction. Biochem. Pharmacol. 75, 112-133.
125. Teicher, M. H., Andersen, S. L. and Hostetter, J. C. (1995) Evidence for dopamine receptor pruning between adolescence and adulthood in striatum but not nucleus accumbens. Dev. Brain. Res. 89, 167-172.
126. Teicher, M. H., Anderson, C. M., Polcari, A., Glod, C. A., Maas, L. C. and Renshaw, P. F. (2000). Functional defi cits in basal ganglia of children with attention-defi cit hyperactivity disorder shown with functional magnetic resonance imaging relaxometry. Nat. Med. 6, 470-473.
127. Thomas, U. (2002) Modulation of synaptic signalling complexes by Homer proteins. J. Neurochem. 81, 407-413.
128. Toda, S., Shen, H. W., Peters, J., Cagle, S. and Kalivas, P. W. (2006) Cocaine increases actin cycling: Effects in the reinstatement model of drug seeking. J. Neurosci. 26, 1579.
129. Todtenkopf, M. S., Parsegian, A., Naydenov, A., Neve, R. L., Konradi, C. and Carlezon, Jr. W. A. (2006) Brain reward regulated by AMPA receptor subunits in nucleus accumbens shell. J. Neurosci. 26, 11665-11669.
130. Unal, C. T., Beverley, J. A., Willuhn, I. and Steiner, H. (2009) Longlasting dysregulation of gene expression in corticostriatal circuits after repeated cocaine treatment in adult rats: effects on zif 268 and homer 1a. Eur J. Neurosci. 21, 1615-1626.
131. van der Kooij, M. A. and Glennon, J. C. (2007) Animal models concerning the role of dopamine in attention-defi cit hyperactivity disorder. Neurosci. Biobehav. Rev. 31, 597-618.
132. Vanderschuren, L. J. and Kalivas, P. W. (2000) Alterations in dopaminergic and glutamatergic transmission in the induction and expression of behavioral sensitization: A critical review of preclinical studies. Psychopharmacol. 151, 99-120.
133. Vendruscolo, L. F., Izidio, G. S. and Takahashi, R. N. (2009) Drug reinforcement in a rat model of attention defi cit/hyperactivity disorderthe spontaneously hypertensive rat (SHR). Curr. Drug Abuse Rev. 2, 177-183.
134. Vezina, P. (2004) Sensitization of midbrain dopamine neuron reactivity and the self-administration of psychomotor stimulant drugs. Neurosci. Biobehav. Rev. 27, 827-839.
135. Volkow N. D. and Swanson, J. M. (2003) Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. Am. J. Psychiatry. 160, 1909-1918.
136. Volkow, N. D., Fowler, J. S., Wang, G. J., Ding, Y. S. and Gatley, S. J., (2002a) Role of dopamine in the therapeutic and reinforcing effects of methylphenidate in humans: results from imaging studies. Eur. J. Neuropsychopharmacol. 12, 557-566.
137. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Gatley, S. J., Wong, C., Hitzemann, R. and Pappas, N. R. (1999) Reinforcing effects of psychostimulants in humans are associated with increases in brain dopamine and occupancy of D(2) receptors. J. Pharmacol. Exp. Ther. 291, 409-415.
138. Volkow, N. D., Wang, G. J., Fowler, J. S., Thanos, P. P., Logan, J. and Gatley, S. J., (2002b) Brain DA D2 receptors predict reinforcing effects of stimulants in humans: replication study. Synapse 46, 79-82.
139. Walker, P. D., Capodilupo J. G., Wolf W. A. and Carlock, L. R. (1996) Preprotachykinin and preproenkephalin mRNA expression within striatal subregions in response to altered serotonin transmission. Brain Res. 732, 25-35.
140. Wee, S. and Woolverton, W. L. (2004) Evaluation of the reinforcing effects of atomoxetine in monkeys: comparison to methylphenidate and desipramine. Drug and Alc. Dep. 75, 271-276.
141. White, F. J. and Kalivas, P. W. (1998) Neuroadaptations involved in amphetamine and cocaine addiction. Drug and Alc. Dep. 51, 141-153.
142. White, F. J. and Wang, R. Y. (1984) Electrophysiological evidence for A10 dopamine autoreceptor subsensitivity following chronic d-amphetamine treatment. Brain Res. 309, 283-292.
143. White, F. J., Hu, X. T., Henry, D. J. and Zhang, X. F. (1995) Neurophysiological alterations in the mesocorticolimbic dopamine system during repeated cocaine administration. In The Neurobiology of Cocaine: Cellular and Molecular Mechanisms (R. P. Jr. Hammer, Ed.), pp. 95-115. CRC Press, Boca Raton.
144. White, F. J., Hu, X. T., Zhang, X. F. and Wolf, M. E. (1995) Repeated administration of cocaine or amphetamine alters neuronal responses to glutamate in the mesoaccumbens dopamine system. J. Pharmacol. Exp. Ther. 273, 445-454.
145. White, F. J. and Wolf, M. E. (1991) Psychomotor stimulants. In The Biological Basis of Drug Tolerance and Dependence (J. A. Pratt, Ed.), pp. 153-197. Academic Press, London,
146. Wigal, S. B., McGough, J. J., McCracken, J. T., Biederman, J., Spencer, T. J., Posner, K. L., Wigal, T. L., Kollins, S. H., Clark, T. M., Mays, D. A., Zhang, Y. and Tulloch, S. J. (2005) A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention defi cit/hyperactivity disorder. J. Atten. Disord. 9, 275-289.
147. Wilens, T. E., Faraone, S. V., Biederman, J. and Gunawardene, S. (2003) Does stimulant therapy of attention-deficit/hyperactivity disorder beget later substance abuse? A meta-analytic review of the literature. Pediatrics 111, 179-185.
148. Wilens, T. E., Adler, L. A., Adams, J., Sgambati, S., Rotrosen, J., Sawtelle, R., Utzinger, L. and Fusillo, S. (2008) Misuse and diversion of stimulants prescribed for ADHD: a systematic review of the literature. J Am. Acad. Child. Adolesc. Psychiatry 47, 21-31.
149. Willuhn, I., Sun, W. and Steiner, H. (2003) Topography of cocaineinduced gene regulation in the rat striatum: relationship to cortical inputs and role of behavioral context. Eur. J. Neurosci. 17, 1053-1066.
150. Xiao, B., Tu, J. C. and Worley. P. (2000) Homer: a link between neural activity and glutamate receptor function. Curr. Opin. Neurobiol. 10, 370-374.
151. Xue, C. J., Ng, J. P., Li, Y. and Wolf, M. E. (1996) Acute and repeated systemic amphetamine administration: Effects on extracellular glutamate, aspartate, and serine levels in rat ventral tegmental area and nucleus accumbens. J. Neurochem. 67, 352-363.
152. Yang, P., Behrang, A., Swann, A. and Nachum, D. (2003) Strain differences in the behavioral responses of male rats to chronically administered methylphenidate. Brain Res. 971, 139-152.
153. Yano, M. and Steiner, H. (2005a) Methylphenidate (Ritalin) induces Homer 1a and zif 268 expression in specifi c corticostriatal circuits. Neurosci. 132, 855-865.
154. Yano, M. and Steiner, H. (2005b) Topography of methylphenidate (Ritalin)-induced gene regulation in the striatum: differential effects on c-fos, substance P and opioid peptides. Neuropsychopharmacol. 30, 901-915.
155. Yano, M., Beverley, J. A. and Steiner, H. (2006) Inhibition of methylphenidate- induced gene expression in the striatum by local blockade of D1 receptors: Interhemispheric effects. Neurosci. 140, 699-709.
156. Yano, M. and Steiner, H. (2007) Methylphenidate and cocaine:the same effects on gene regulation. Trends in Pharmacol Sci. 28, 588-596.
157. Zhang, X. F., Hu, X. T., White, F. J. and Wolf, M. E. (1997) Increased responsiveness of ventral tegmental area dopamine neurons to glutamate after repeated administration of cocaine or amphetamine is transient and selectively involves AMPA receptors. J. Pharmacol. Exp. Ther. 281, 699-706.